Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomark Diagnostics Inc (OP: BMKDF )

0.2051 +0.0021 (+1.03%)
Streaming Delayed Price Updated: 1:52 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 25,200
Open 0.1929
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.2030
Today's Range 0.1800 - 0.2051
52wk Range 0.1430 - 0.2531
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMark Announces Closing of $1.9 Million Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - December 29, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"... 
Via Newsfile
BioMark Announces Recent New Patent Granted in Canada to Support Its Liquid Biopsy Based Legacy Assay
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2023) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF)... 
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property

Performance

YTD
+10.69%
+10.69%
1 Month
-10.83%
-10.83%
3 Month
+4.43%
+4.43%
6 Month
+4.86%
+4.86%
1 Year
+2.55%
+2.55%

More News

Read More
BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise Term
Via Newsfile
BioMark Strengthens and Expands Its Strategic Advisory Team in Pursuit of Commercialization Initiatives
Via Newsfile
Topics Artificial Intelligence
Exposures Artificial Intelligence
BioMark Announces Financial Contribution from the City of Quebec to Support Commercialization Initiatives of Its Proprietary Lung Cancer Detection Test
Via Newsfile
BioMark to Unveil Results of Its Early Breast Cancer Study at the Upcoming San Antonio Breast Cancer Symposium
Via Newsfile
BioMark Appoints Kevin J. Cosgriff to Its Strategic Advisory Team
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
Japan Patent Office (JPO) Issued BioMark Patent with Claims Covering Its Lung Cancer Urine Based Liquid Biopsy Assay
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
BioMark Unveils Significant Scientific Advancements from Its Leading Liquid Biopsy Technology at ASCO 2023 Annual Meeting
Via Newsfile
BioMark Announces the U.S. Patent and Trademark Office Granted Patent with Claims Covering Its Lung Cancer Liquid Biopsy Assay
Via Newsfile
Topics Death Intellectual Property
Exposures Death Intellectual Property
BioMark Latest Results Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023
Via Newsfile
Canadian Cancer Diagnostic Company BioMark Working On Early Lung Detection Assay
Via Benzinga
BioMark Presents Novel Liquid Biopsy Data in Pulmonary Neuroendocrine Tumors
Via Newsfile
Biomark Receives Funding Supporting Research and Development Project for Cancer Treatment Monitoring
Via Newsfile
BioMark Announces Update from Ongoing Clinical Trial Using Its Lung Cancer Liquid Biopsy Test as It Prepares for Commercial Launch
Via Newsfile
Topics Climate Change
Exposures Climate
BioMark to Collaborate with Astrazeneca, Pfizer Canada and The IUCPQ Foundation in a $3.5m Project to Improve Early Detection of Lung Cancer
Via Newsfile
Topics Artificial Intelligence Death
Exposures Artificial Intelligence Death
Detecting Early Cancer Screening Stocks At An Early Stage Is Critical
Via Benzinga
Liquid Biopsy Company BioMark to Present at the 3rd Annual Congress of the International Society of Liquid Biopsy to Be Held October 22, 2021
Via Newsfile
A Cryptocurrency, A Big Board Name, And A Penny Stock Look Bullish Going Into The Week
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.